Receive Our Newsletter

Hemophilia Bleeding Disorder Industry News
Industry News

Biogen Announces Intent to Spin off Its Hemophilia Business

Note: The below is an edited version of a press release from Biogen Inc. The original release can be read in its entirety here. Biogen Inc. announced on Tuesday, May 3, 2016 that it intends to spin off its hemophilia business as an independent, publicly traded company. The strategic goal of this transaction is to […]

Industry News

FDA Approves Needle-Free Transfer Device for Hemophilia A Product

Note: The following in an edited press release from Kedrion Biopharma. The original release can be read in its entirety here. Kedrion Biopharma has gained approval from the U.S. Food and Drug Administration to package Koāte® Double Viral Inactivation (DVI) Antihemophilic Factor (human) with Mix2Vial™, a needle-free transfer device. The new packaging is designed to offer hemophilia […]

Industry News

FDA Approves New Recombinant Factor Following LEOPOLD Trials

Note: The following is an edited version of a press release from Bayer. The original press release can be found here.  The U.S. Food and Drug Administration (FDA) has approved Bayer’s KOVALTRY® Antihemophilic Factor (Recombinant), an unmodified, full-length factor VIII compound for the treatment of hemophilia A in children and adults. The approval is based […]

Industry News

FDA Approves First 14-Day Hemophilia B Treatment

Note: The following is an edited form of a press release from the FDA . The original form of the release can be read here. The U.S. Food and Drug Administration approved on Friday, March 4, Idelvion, Coagulation Factor IX (Recombinant), Albumin Fusion Protein, for use in children and adults with Hemophilia B. Idelvion is the […]

Industry News

FDA Gives Orphan Drug Designation for Hemophilia A Gene Therapy

Note: The below is an edited version of a press release by BioMarin Pharmaceutical Inc. The original release can be read in its entirety here. BioMarin Pharmaceutical Inc. announced on Tuesday, March 1, that BMN 270, an investigational gene therapy for the treatment of patients with hemophilia A, has been granted orphan drug designation by […]

Industry News

FDA Approves Treatment of Chronic Hepatitis C Genotypes 1 and 4

Note: The following is an edited form of a press release from the Food and Drug Administration. The original form of the release can be read here. On Thursday, January 28, the U.S. Food and Drug Administration approved Zepatier (elbasvir and grazoprevir) with or without ribavirin for the treatment of chronic hepatitis C virus (HCV) […]

Industry News

Future Bisomilars: Pros and Cons

Note: This story was originally published in the January 2016 issue of BioSupply Trends Quarterly. It can be read in its original format here. By Meredith Whitmore In this brave new world of medicines, more and more physicians are prescribing a biologic. Perhaps they have even witnessed a patient’s remarkable transformation thanks to biologics such […]

Industry News

Drugmaker Shire Wins Baxalta for $32 Billion After Six-Month Pursuit

Note: The following story was published by Reuters on Monday, January 11, 2016 . It can be found here. Drugmaker Shire Plc clinched its six-month pursuit of Baxalta International Inc on Monday with an agreed $32 billion cash and stock offer, catapulting it to a leading position in treating rare diseases. The London-listed group, which first […]

Industry News

uniQure Announces Preliminary Results from Hemophilia B Gene Therapy Trial

Note: the following is the  edited form of a  press releaseoriginally published by uniQure. The full release can be read here.  On Thursday, January 7, 2016, uniQure N.V. announced preliminary topline results from the low-dose cohort of an ongoing Phase I/II clinical trial being conducted in adult hemophilia B patients treated with uniQure’s novel AAV5/FIX […]

Industry News

Octapharma Announces US Availability of NUWIQ

 Note: The following is an edited press release from Octapharma USA. The original release can be read in its entirety here. Octapharma USA announced on Monday, January 4, 2016 that NUWIQ®, Antihemophilic Factor (Recombinant), is now commercially available. NUWIQ® is indicated for the treatment and control of bleeding, perioperative (surgical) management, and routine prophylaxis to reduce […]

Page 5 of 2212345678910NextLast »

Assisting and Advocating for the Bleeding Disorders Community